FIELD: medicine, pharmaceutics.
SUBSTANCE: invention proposes application of αγβ integrn antagonist for obtainig a remedy for treatment of hepatic billary fibrosis, the antagonist being 3-{3-benziloxy-2-[5-(pyridine-2-ylamino) pentanoylamino]propanoylamino}-3-(3.5-dichlorphenyl)-propionic acid It is demonstrated that the compound inhibits αv integins, particularly αvβ3 and αvβ6 integrins, effect decreasing regulation of fibrogenesis through inhibiting cellular migration and migration of profibrogen molecules (e.g. collagenase, TMP-1), and cytokines (e.g., CTGF) with the help of activated stellar hepatic cells /miofibroblasts, activated epithelium and endothelium.
EFFECT: antagonist can effectively prevent, reduce or even cause regression of secondary hepatic billary fibrosis by reducing total amount of collagen in the liver by 50-70% after 5-6 week-long occlusion of the bile duct.
7 dwg, 1 tbl
